Key facts
- This page summarizes David J. Mack's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 May 2025, 19:23.
David J. Mack - 30 Apr 2025 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)
- Reporting relationship
- Director
- Issuer ticker
- BTAI
- Reported as of
- 30 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 May 2025, 19:23:09 UTC
- Prior SEC filing
- 01 Apr 2025
- Next SEC filing
- 02 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard Steinhart, Attorney-in-Fact for David J. Mack
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David J. Mack filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 01 May 2025.
Change
- Previous filing in this sequence was filed on 01 Apr 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BTAI
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,693
- Change %
- +20%
- Price
- Shares after
- 10,158
- Date
- 30 Apr 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BTAI
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,693
- Change %
- -14%
- Price
- $0.000000
- Shares after
- 10,159
- Date
- 30 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,693
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period.